# A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies

> **NCT06252298** · PHASE1 · RECRUITING · sponsor: **Sinocelltech Ltd.** · enrollment: 74 (estimated)

## Conditions studied

- Relapsed or Refractory Hematologic Malignancies

## Interventions

- **BIOLOGICAL:** SCTC21C

## Key facts

- **NCT ID:** NCT06252298
- **Lead sponsor:** Sinocelltech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-28
- **Primary completion:** 2025-08-28
- **Final completion:** 2027-02-28
- **Target enrollment:** 74 (ESTIMATED)
- **Last updated:** 2024-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06252298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06252298, "A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06252298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*